Search markets
Search icon A magnifying glass. It indicates, "Click to perform a search".
Search markets
Search icon A magnifying glass. It indicates, "Click to perform a search".
Close icon Two crossed lines that form an 'X'. It indicates a way to close an interaction, or dismiss a notification.

AbbVie Inc Stock , ABBV

154.20 -0.02 -0.01%
Official Close 3/17/2023 NYSE
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar

Is AbbVie stock a Buy, Sell or Hold? AbbVie stock has received a consensus rating of buy. The average rating score is and is based on 29 buy ratings, 14 hold ratings, and 2 sell ratings.
What was the 52-week low for AbbVie stock? The low in the last 52 weeks of AbbVie stock was 134.09. According to the current price, AbbVie is 115.01% away from the 52-week low.
What was the 52-week high for AbbVie stock? The high in the last 52 weeks of AbbVie stock was 175.91. According to the current price, AbbVie is 87.67% away from the 52-week high.
What are analysts forecasts for AbbVie stock? The 45 analysts offering price forecasts for AbbVie have a median target of 157.38, with a high estimate of 200.00 and a low estimate of 113.00. The median estimate represents a 97.99 difference from the last price of 154.22.

AbbVie Stock Snapshot

154.07
Bid
1,100.00
Bid Size
154.16
Ask
25,300.00
Ask Size
3/17/2023
Date
4:15 PM
Time
19.25 M
Volume
155.30
Prev. Close
155.78
Open
272.72 B
Market Cap
1.77 B
Number of Shares
151.90
Day Low
156.05
Day High
154.22
134.09
52 Week Low
175.91
52 Week High
154.22
5.92
Dividend
3.86
Dividend Yield
11.82
P/E Ratio
99.85
Free Float in %
11.09
EPS 2023
10.39
Book Value per Share
12.77
Cash Flow per Share

AbbVie Historical Prices

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

AbbVie Analyst Data

Total Analysts: 45
Buy Ratings: 29 Neutral Ratings: 14 Sell Ratings: 2
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 113.00 Median: 157.38 Highest: 200.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

AbbVie Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
03/01/23 Guggenheim
Maintained Buy $172
02/22/23 Wolfe Research
Downgraded to Hold
02/10/23 SVB Leerink
Upgraded to Hold $153
02/10/23 Atlantic Equities
Maintained Hold $154
02/10/23 Morgan Stanley
Maintained Buy $178
02/10/23 Piper Sandler
Maintained Buy $163
02/06/23 BMO Capital Markets
Maintained Buy $167
01/17/23 Piper Sandler
Maintained Buy $157
12/06/22 Morgan Stanley
Maintained Buy $182
11/18/22 Credit Suisse
Maintained Buy $170
10/31/22 Atlantic Equities
Maintained Hold $157
10/31/22 Morgan Stanley
Maintained Buy $178
10/31/22 BMO Capital Markets
Maintained Buy $169
10/31/22 Barclays Capital
Maintained Hold $155
10/11/22 Morgan Stanley
Maintained Buy $185
09/30/22 SVB Leerink
Maintained Sell $135
08/24/22 Argus Research Company
Maintained Buy $155
08/01/22 UBS
Maintained Hold $146
08/01/22 Morgan Stanley
Maintained Buy $188
08/01/22 Barclays Capital
Maintained Hold $160
08/01/22 Atlantic Equities
Maintained Hold $162
07/08/22 Morgan Stanley
Maintained Buy $191
05/23/22 SVB Leerink
Maintained Sell $140
05/02/22 Morgan Stanley
Maintained Buy $188
05/02/22 Wells Fargo & Co
Maintained Buy $200
04/25/22 BMO Capital Markets
Maintained Buy $174
04/12/22 Goldman Sachs
Maintained Hold $140
04/12/22 Barclays Capital
Maintained Hold $174
04/06/22 Morgan Stanley
Maintained Buy $192
02/28/22 UBS
Downgraded to Hold $147
02/04/22 Mizuho
Maintained Buy $166
02/03/22 Barclays Capital
Maintained Hold $150
01/24/22 Morgan Stanley
Maintained Buy $142
01/20/22 Barclays Capital
Maintained Hold $133
01/12/22 BMO Capital Markets
Maintained Buy $153
01/05/22 Mizuho
Maintained Buy $154
12/17/21 Goldman Sachs
Maintained Hold $113
12/09/21 Wells Fargo & Co
Maintained Buy $165
11/01/21 Barclays Capital
Maintained Hold $118
11/01/21 Morgan Stanley
Maintained Buy $124
11/01/21 SVB Leerink
Maintained Buy $135
08/20/21 SVB Leerink
Maintained Buy $148
08/02/21 Mizuho
Maintained Buy $131
08/02/21 SVB Leerink
Maintained Buy $145
05/03/21 BMO Capital Markets
Maintained Buy $129
03/30/21 SVB Leerink
Maintained Buy $144

AbbVie Estimates* in USD

  2023 2024 2025 2026 2027
Revenue 52,702 52,614 55,384 58,429 61,594
Dividend 5.92 6.12 6.39 6.83 7.34
Dividend Yield (in %) 3.86 % 3.99 % 4.17 % 4.46 % 4.78 %
EPS 11.09 11.11 12.18 13.17 14.50
P/E Ratio 14.10 14.06 12.83 11.86 10.77
EBIT 25,054 24,992 26,940 29,059 31,467
EBITDA 25,908 25,869 27,660 28,870 33,470
Net Profit 19,737 19,758 21,536 23,114 25,452
Net Profit Adjusted 19,737 19,758 21,536 23,114 25,452
Pre-Tax Profit 23,467 23,437 25,664 26,746 30,256
Net Profit (Adjusted) 18,851 18,862 19,275 16,450 -
EPS (Non-GAAP) ex. SOE 11.09 11.11 12.18 13.17 14.50
EPS (GAAP) 8.02 8.22 9.22 10.27 12.76
Gross Income 43,728 43,273 44,978 47,903 50,605
Cash Flow from Investing -1,803 -1,910 -1,990 -2,542 -2,914
Cash Flow from Operations 24,893 22,158 23,108 24,039 25,932
Cash Flow from Financing -14,365 -16,120 -18,170 -17,868 -16,734
Cash Flow per Share 12.77 12.69 14.04 11.98 -
Free Cash Flow 20,596 21,154 23,717 27,272 27,087
Free Cash Flow per Share 12.81 11.80 - - -
Book Value per Share 10.39 10.55 11.89 11.97 -
Net Debt 47,055 39,923 30,565 22,849 9,772
Research & Development Exp. 6,773 6,811 6,989 7,241 7,418
Capital Expenditure 778 786 810 766 788
Selling, General & Admin. Exp. 12,445 12,411 12,585 12,758 13,025
Shareholder’s Equity 21,119 22,497 26,206 33,586 44,301
Total Assets 147,560 145,513 144,897 150,820 161,716
  Previous Quarter
ending 12/31/22 		Current Quarter
ending 03/31/23 		Next Quarter
ending 06/30/23 		Current Year
ending 12/31/23 		Next Year
ending 12/31/24
Earnings Estimates
No. of Analysts 17 17 16 22 21
Average Estimate 3.555 USD 2.557 USD 2.876 USD 11.087 USD 11.115 USD
Year Ago 3.310 USD 3.160 USD 3.370 USD 13.770 USD 11.087 USD
Publish Date 2/9/2023 4/27/2023 7/28/2023 - -
Revenue Estimates
No. of Analysts 13 14 13 22 21
Average Estimate 15,322 USD 12,130 USD 13,367 USD 52,702 USD 52,614 USD
Year Ago 14,886 USD 13,538 USD 14,583 USD 58,054 USD 52,702 USD
Publish Date 2/9/2023 4/27/2023 7/28/2023 - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

AbbVie Insider Activity

Name Date shares traded shares held Price type (sell/buy) option
Stewart Jeffrey Ryan 03/12/2023 31,315.00 60,941.00 152.27 Sell No
Stewart Jeffrey Ryan 03/12/2023 21,810.00 92,256.00 152.30 Sell No
Stewart Jeffrey Ryan 03/12/2023 21,810.00 114,066.00 54.86 Buy No
Strom Carrie C 03/04/2023 449.00 30,900.00 156.06 Sell No
GONZALEZ RICHARD A 03/02/2023 2,550.00 643,794.00 n/a Sell No
Strom Carrie C 03/01/2023 810.00 31,349.00 155.27 Sell No
RICHMOND TIMOTHY J. 02/28/2023 16,746.00 13,837.00 153.62 Sell No
RICHMOND TIMOTHY J. 02/28/2023 27,395.00 30,583.00 153.08 Sell No
Reents Scott T 02/28/2023 850.00 809.00 153.38 Sell No
Reents Scott T 02/28/2023 15,092.00 1,659.00 153.06 Sell No
SALEKI-GERHARDT AZITA 02/28/2023 780.00 189,849.00 153.39 Sell No
SALEKI-GERHARDT AZITA 02/28/2023 9,220.00 190,629.00 153.05 Sell No
SALEKI-GERHARDT AZITA 02/28/2023 26,990.00 199,849.00 155.00 Sell No
Siatis Perry C 02/28/2023 805.00 10,377.00 153.38 Sell No
Siatis Perry C 02/28/2023 11,330.00 11,182.00 153.06 Sell No
Sorg Elaine K. 02/28/2023 15,003.00 42,829.00 155.00 Sell No
SALEKI-GERHARDT AZITA 02/28/2023 26,990.00 226,839.00 51.42 Buy No
Sorg Elaine K. 02/28/2023 15,003.00 57,832.00 93.50 Buy No
RICHMOND TIMOTHY J. 02/27/2023 35,111.00 57,978.00 154.28 Sell No
GONZALEZ RICHARD A 02/27/2023 113,810.00 646,344.00 154.28 Sell No
Michael Robert A. 02/27/2023 48,335.00 98,645.00 154.28 Sell No
Stewart Jeffrey Ryan 02/27/2023 24,910.00 92,256.00 154.28 Sell No
Reents Scott T 02/27/2023 12,683.00 16,751.00 154.28 Sell No
SALEKI-GERHARDT AZITA 02/27/2023 33,359.00 199,849.00 154.28 Sell No
Siatis Perry C 02/27/2023 9,656.00 22,512.00 154.28 Sell No

AbbVie Dividend Calendar

Date Name Dividend *yield Currency
2022 AbbVie Inc 5.71 3.53 USD
2021 AbbVie Inc 5.31 3.92 USD
2020 AbbVie Inc 4.84 4.52 USD
2019 AbbVie Inc 4.39 4.96 USD
2018 AbbVie Inc 3.95 4.28 USD
2017 AbbVie Inc 2.63 2.72 USD
2016 AbbVie Inc 2.35 3.75 USD
2015 AbbVie Inc 2.10 3.54 USD
2014 AbbVie Inc 1.75 2.67 USD
2013 AbbVie Inc 2.00 3.79 USD
2013 AbbVie Inc 1.60 3.03 USD
2012 AbbVie Inc 0.40 1.17 USD
2011 AbbVie Inc - - USD
2010 AbbVie Inc - - USD
2009 AbbVie Inc - - USD
*Yield of the Respective Date

AbbVie Inc Calendar

Event Estimate Info Date
Earnings Report 2.557 USD Q1 2023 Earnings Release 04/27/2023
Earnings Report 2.876 USD Q2 2023 Earnings Release 07/28/2023
Earnings Report - Q3 2023 Earnings Release 11/03/2023
Earnings Report - Q4 2023 Earnings Release 01/26/2024

AbbVie Inc Past Events

Event Actual EPS Info Date
Earnings Report 3.600 USD Q4 2022 Earnings Release 02/09/2023
Press Conference - - 07/29/2022
Shareholders' Meeting - - 05/06/2022

AbbVie Profile

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Moody’s Daily Credit Risk Score

Risk
  • Low
  • Medium
  • High
4
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

AbbVie Shareholder

Owner in %
Freefloat 99.86
Vanguard Group, Inc. (Subfiler) 8.51
State Street Corp. 4.41
Vanguard Total Stock Market Index Fund 3.08
BlackRock Fund Advisors 3.03
Capital Research & Management Co. (International Investors) 2.66
JPMorgan Investment Management, Inc. 2.35
Vanguard 500 Index Fund 2.32
BlackRock Institutional Trust Co. NA 2.19
Capital Research & Management Co. (Global Investors) 2.07
Geode Capital Management LLC 1.91
T. Rowe Price Associates, Inc. (Investment Management) 1.15
Fidelity 500 Index Fund 1.09
SPDR S&P 500 ETF Trust 1.08
Norges Bank (13F) 1.06
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.

AbbVie Management

Name Job
Richard A. Gonzalez Chairman & Chief Executive Officer
Jeffrey Ryan Stewart Chief Commercial Officer & Executive VP
Scott T. Reents Chief Financial Officer & Executive Vice President
Timothy J. Richmond Chief Human Resources Officer & Executive VP
Laura J. Schumacher Chief Legal Officer
Thomas J. Hudson Chief Scientific Officer, Senior VP-R&D
Henry O. Gosebruch Chief Strategy Officer & Executive Vice President
Azita Saleki-Gerhardt Executive Vice President-Operations
Liz Shea Head-Investor Relations
Roxanne Schuh Austin Independent Director
Edward J. Rapp Independent Director
William H. L. Burnside Independent Director
Robert J. Alpern Independent Director
Frederick H. Waddell Independent Director
Thomas C. Freyman Independent Director
Brett J. Hart Independent Director
Rebecca Brown Roberts Independent Director
Melody B. Meyer Independent Non-Executive Director
Glenn Fletcher Tilton Lead Independent Director
Perry C. Siatis Secretary, Executive VP & General Counsel
Carrie Strom Senior VP & President-Global Allergan Aesthetics
Kevin K. Buckbee Senior Vice President & Controller
Robert A. Michael Vice Chairman & President
Brian L. Durkin Vice President
Chris Boone Vice President & Global Head-Health Economics
Katherine Rielly-Gauvin Vice President-Global Commercial Development
Todd D. Bosse Vice President-Investor Relations
Esteban Plata Vice President-Western Europe & Canada